Dr. Harbour is an ocular oncologist, cancer researcher, educator and innovator in the development of precision medicine for patients with eye cancers, such as uveal melanoma and retinoblastoma. He is currently Professor and Vice Chairman at Bascom Palmer Eye Institute and Associate Director for Basic Science at Sylvester Comprehensive Cancer Center of the University of Miami Miller School of Medicine. For over two decades, he has been the principal investigator on grants from the National Cancer Institute and National Eye Institute, as well as many private foundations. He has authored more than 180 peer-reviewed articles, many in high profile journals such as Science, Cell, and Nature family journals. Through his distinctive fusion of clinical experience and laboratory research, Dr. Harbour has contributed numerous advances to medicine. He invented and licensed the first and only prospectively validated molecular prognostic test for uveal melanoma and discovered two of the most important driver mutations in this cancer (BAP1 and SF3B1). His work led to the discovery of the BAP1 familial cancer syndrome. His research focuses on genetics, genomics, cell biology and animal models as discovery tools. His laboratory is now a leading contributor to discovery using single cell sequencing technologies.